Abstract
All patients with carcinoma of the breast seen in this Unit since 1970 were reviewed to study the incidence, prognosis, morbidity and response to treatment of bone metastases. The biological characteristics of the primary tumour were compared in patients relapsing first in bone or liver. Sixty-nine percent of patients dying with breast cancer had bone metastases and bone was the commonest site of first distant relapse. Bone relapse was more common in receptor positive or well differentiated (grade 1) tumours. The median survival was 24 months in those with disease apparently confined to the skeleton compared with 3 months after first relapse in liver. Ten percent of patients with breast cancer developed hypercalcaemia. All had metastatic disease and 85% had widespread skeletal involvement. Fifteen percent of patients with disease confined to the skeleton developed hypercalcaemia. The response in bone to primary endocrine therapy, and chemotherapy, was apparently less than the overall response achieved. A large proportion had apparently static disease reflecting the insensitivity of the UICC assessment criteria. The duration of survival in these patients was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Coleman, R., Rubens, R. The clinical course of bone metastases from breast cancer. Br J Cancer 55, 61–66 (1987). https://doi.org/10.1038/bjc.1987.13
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.13
This article is cited by
-
Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer
Cancer Imaging (2023)
-
Controlled tumor heterogeneity in a co-culture system by 3D bio-printed tumor-on-chip model
Scientific Reports (2023)
-
Bone serves as a transfer station for secondary dissemination of breast cancer
Bone Research (2023)
-
Evolving cancer–niche interactions and therapeutic targets during bone metastasis
Nature Reviews Cancer (2022)
-
Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis
Cancer Gene Therapy (2022)